PFIZER ZOLOFT PROMOTION OF "APPROVABLE" OCD INDICATION QUESTIONED IN FDA WARNING LETTER; SERTRALINE USE IN POST-MYOCARDIAL INFARCTION SETTING ALSO CHALLENGED
FDA is objecting to Pfizer's references to studies of the antidepressant Zoloft (sertraline) for a pending indication for use in obsessive-compulsive disorder as one of the complaints outlined in an Aug. 1 warning letter from the Division of Drug Marketing, Advertising & Communications.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth